[go: up one dir, main page]

UA98772C2 - Производные циклопропиламина как модуляторы н3-гистаминового рецептора - Google Patents

Производные циклопропиламина как модуляторы н3-гистаминового рецептора

Info

Publication number
UA98772C2
UA98772C2 UAA200900472A UAA200900472A UA98772C2 UA 98772 C2 UA98772 C2 UA 98772C2 UA A200900472 A UAA200900472 A UA A200900472A UA A200900472 A UAA200900472 A UA A200900472A UA 98772 C2 UA98772 C2 UA 98772C2
Authority
UA
Ukraine
Prior art keywords
histamin
receptor modulators
amine derivatives
cyclopropyl amine
compounds
Prior art date
Application number
UAA200900472A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хуацин Лю
Лоренс А. Блек
Юссеф Д. Беннани
Марлон Д. КАУЭРТ
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA98772C2 publication Critical patent/UA98772C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы (I)(I),полезны при лечении состояний или нарушений, которые предотвращают или которые облегчают с помощью лигандов Н-гистаминовых рецепторов.Также раскрыты фармацевтические композиции, которые содержат лиганды Н-гистаминовых рецепторов, применение таких соединений и композиций и способ получения соединений, которые входят в область, которая определяется формулой (I).
UAA200900472A 2006-06-23 2007-06-22 Производные циклопропиламина как модуляторы н3-гистаминового рецептора UA98772C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81593406P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
UA98772C2 true UA98772C2 (ru) 2012-06-25

Family

ID=38670977

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200900472A UA98772C2 (ru) 2006-06-23 2007-06-22 Производные циклопропиламина как модуляторы н3-гистаминового рецептора

Country Status (22)

Country Link
US (1) US8829041B2 (ru)
EP (1) EP2049472B1 (ru)
JP (1) JP5203360B2 (ru)
KR (1) KR20090024811A (ru)
CN (2) CN103382174A (ru)
AU (1) AU2007260836B2 (ru)
BR (1) BRPI0712823A2 (ru)
CA (1) CA2655604C (ru)
CR (1) CR10540A (ru)
DO (1) DOP2011000283A (ru)
EC (1) ECSP099046A (ru)
ES (1) ES2533009T3 (ru)
IL (1) IL196094A0 (ru)
MX (1) MX2008016343A (ru)
NO (1) NO20090282L (ru)
NZ (2) NZ611323A (ru)
RU (1) RU2449989C2 (ru)
SG (1) SG173312A1 (ru)
TW (1) TW200808773A (ru)
UA (1) UA98772C2 (ru)
UY (1) UY31527A1 (ru)
WO (1) WO2007150010A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132914A2 (en) * 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
RU2449989C2 (ru) 2006-06-23 2012-05-10 Эбботт Лэборетриз Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ584100A (en) 2007-08-22 2011-07-29 Astrazeneca Ab Cyclopropyl amide derivatives
AU2013216616B2 (en) * 2007-12-14 2016-04-21 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
BR112012020782A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab composto, e, processo para preparar um composto
EP2536701A4 (en) * 2010-02-18 2014-05-07 Astrazeneca Ab SOLID FORMS WITH A CYCLOPROPYLAMID DERIVATIVE
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128365C (ru) 1963-11-05
FR2508033A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
DE3582728D1 (de) 1985-01-17 1991-06-06 Ici Plc Tertiaere aminoverbindungen.
GB8615313D0 (en) 1986-06-23 1986-07-30 Ici Plc Chemical process
GB8621790D0 (en) 1986-09-10 1986-10-15 Ici Plc Tertiary amine compounds
GB2210364A (en) 1987-09-29 1989-06-07 Ici Plc Cyclopropane ring-containing tertiary amine derivatives
US5086054A (en) * 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9401436D0 (en) 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
FR2716192B1 (fr) 1994-02-17 1996-04-12 Rhone Poulenc Agrochimie Dérivés de 2-imidazoline-5-ones fongicides.
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
DE19821002A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2000047358A (ja) 1998-07-28 2000-02-18 Fuji Photo Film Co Ltd 感光材料処理装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3033100A (en) 1999-01-18 2000-08-01 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
WO2002004433A2 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
JP2004506012A (ja) * 2000-08-17 2004-02-26 グリアテツク・インコーポレイテツド Ｈ３剤としての新規脂環式イミダゾール
US6996472B2 (en) 2000-10-10 2006-02-07 The United States Of America As Represented By The Department Of Health And Human Services Drift compensation method for fingerprint spectra
WO2002044128A2 (en) 2000-11-28 2002-06-06 Sunesis Pharmaceuticals, Inc. Salicylate analogs as interleukin-4 antagonists
JP2002236340A (ja) 2001-02-09 2002-08-23 Konica Corp ハロゲン化銀写真感光材料の自動現像機による処理方法
US6969730B2 (en) * 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
EP2258694A1 (en) 2001-03-16 2010-12-08 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE10153345A1 (de) 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
DE10153347A1 (de) 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinolin-2-on-Verbindungen
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2474214A1 (en) 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2003099276A1 (en) * 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
EP1513842B1 (en) 2002-06-06 2007-03-07 Novo Nordisk A/S Substituted hexahydropyrrolo (1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2004026305A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US7414047B2 (en) 2002-10-23 2008-08-19 Janssen Pharmaceutica N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
AU2003275838A1 (en) 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
JP4820094B2 (ja) 2002-11-12 2011-11-24 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての２環式置換アミン
US7153889B2 (en) * 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
AU2003294909B2 (en) * 2002-12-20 2007-05-17 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
JP4458333B2 (ja) * 2003-02-13 2010-04-28 キヤノン株式会社 露光装置、およびデバイスの製造方法
US7592347B2 (en) 2003-04-23 2009-09-22 Glaxo Group Limited Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
PL1620082T3 (pl) 2003-05-05 2010-10-29 Probiodrug Ag Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
EP1625124A1 (en) 2003-05-06 2006-02-15 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
US7094790B2 (en) * 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
WO2005009471A1 (en) 2003-07-28 2005-02-03 Osaka Industrial Promotion Organization Composition for lowering blood-sugar level
JP4680903B2 (ja) 2003-07-29 2011-05-11 ハイ・ポイント・ファーマスーティカルズ、エルエルシー ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用
GB0319211D0 (en) 2003-08-15 2003-09-17 Koninkl Philips Electronics Nv Antenna arrangement and a module and a radio communications apparatus having such an arrangement
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
WO2005039548A2 (en) * 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
JP4617837B2 (ja) 2003-11-21 2011-01-26 チッソ株式会社 フッ化アルキレンを有する重合性を有する液晶性化合物およびその重合体
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
JP2007519605A (ja) 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
EP1717230B1 (en) * 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
GB0405628D0 (en) 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
JP2005281223A (ja) 2004-03-30 2005-10-13 Chisso Corp １，２−シクロヘキシレン環を有する光学活性化合物、液晶組成物、液晶表示素子、成形体
US7345034B2 (en) * 2004-04-07 2008-03-18 Abbott Laboratories Azacyclosteroid histamine-3 receptor ligands
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
GEP20094826B (en) * 2004-05-07 2009-11-10 Warner Lambert Co 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
US7205316B2 (en) * 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2005123723A1 (en) 2004-06-18 2005-12-29 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
JP4857267B2 (ja) * 2004-06-30 2012-01-18 アサーシス， インク． 認識障害、睡眠障害、肥満及びその他のｃｎｓ障害を治療するためのヒスタミン３受容体インヒビターとなる非イミダゾール第三級アミン
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US20060074103A1 (en) * 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
SI1802307T1 (sl) 2004-10-15 2008-08-31 Glaxo Group Ltd Derivati pirolidina kot ligandi histaminskih receptorjev
US20090306052A1 (en) 2004-12-07 2009-12-10 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1836171A1 (en) 2005-01-07 2007-09-26 Glaxo Group Limited 6-(2,3,4,5-tetrahydro-1h-benzo[d]azepin-7-yloxy)-nicotamide derivatives as radiolabelled ligands
AU2006213206A1 (en) 2005-02-14 2006-08-17 Banyu Pharmaceutical Co., Ltd Crystal of 4(3H)-quinazolinone derivative
WO2006090142A1 (en) 2005-02-24 2006-08-31 Glaxo Group Limited l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST
JP2008533117A (ja) 2005-03-14 2008-08-21 グラクソ グループ リミテッド ヒスタミンｈ３受容体に対して親和性を有する縮合チアゾール誘導体
EP1707204A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
WO2006124687A1 (en) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
JP2008540618A (ja) 2005-05-18 2008-11-20 ブルスター，ジークフリート ソマトスタチン受容体サブタイプ１及び／又は４に選択的なペプチド模倣薬
WO2006132914A2 (en) 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
US20090306375A1 (en) 2005-06-07 2009-12-10 Satoshi Kii Process for production of 4(3H)-quinazolinone derivative
WO2007003604A2 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
AU2006266713A1 (en) 2005-07-05 2007-01-11 Banyu Pharmaceutical Co., Ltd. Method for producing 4(3H)-quinazolinone derivative
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20090203750A1 (en) 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
ES2342323T3 (es) * 2005-09-16 2010-07-05 Janssen Pharmaceutica N.V. Ciclopropilaminas como moduladores del receptor h3 de histamina.
CA2623025A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
US7576110B2 (en) 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
AU2006308167A1 (en) 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
RU2449989C2 (ru) 2006-06-23 2012-05-10 Эбботт Лэборетриз Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора
JP5335675B2 (ja) * 2006-07-25 2013-11-06 セファロン、インク． ピリジジノン誘導体
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064310A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Mixed opioid receptor active compounds
KR20090091315A (ko) 2006-11-29 2009-08-27 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 1형 효소의 억제제
KR101108109B1 (ko) * 2007-01-22 2012-02-06 화이자 프로덕츠 인코포레이티드 치료 화합물의 토실레이트 염 및 이의 약학 조성물
CL2008000596A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
US20100249144A1 (en) 2007-06-28 2010-09-30 Demong Duane Eugene Substituted piperazines as cb1 antagonists
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
RS55735B1 (sr) * 2007-08-03 2017-07-31 Summit (Oxford) Ltd Kombinacije lekova za lečenje dišenove mišićne distrofije
NZ584100A (en) 2007-08-22 2011-07-29 Astrazeneca Ab Cyclopropyl amide derivatives
ES2384414T3 (es) 2007-09-06 2012-07-04 Glaxo Group Limited Derivado de piperazina que tiene afinidad por el receptor H3 de histamina
US20100317679A1 (en) 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2234978B1 (en) 2007-12-20 2015-02-25 AstraZeneca AB Carbamoyl compounds as dgat1 inhibitors 190
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
WO2009092764A1 (en) * 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
RU2010137114A (ru) 2008-02-07 2012-03-20 Эбботт Лэборетриз (Us) Амидные производные как позитивные аллостерические модуляторы и способы их применения
WO2009115874A2 (en) 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
WO2009124553A2 (en) 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
US20110098300A1 (en) 2008-06-06 2011-04-28 Ucb Pharma, S.A. Compounds Comprising A Cyclobutoxy Group
JP2011524872A (ja) 2008-06-11 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション Ｆａａｈの阻害剤として有用なピラゾール誘導体
US8268846B2 (en) 2008-07-11 2012-09-18 Abbott Laboratories Amino heterocyclic linked pyrimidine derivatives
WO2010007382A1 (en) 2008-07-18 2010-01-21 Takeda Pharmaceutical Company Limited. Benzazepine derivatives and their use as hstamine h3 antagonists
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
PL2328930T3 (pl) 2008-08-20 2015-05-29 Probiodrug Ag Przeciwciała skierowane przeciwko piroglutaminianowi białka chemotaktycznego monocytów typu 1 (MCP-1 N1pE)
EP2379565A1 (en) 2008-12-19 2011-10-26 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20100227876A1 (en) * 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
TW201141485A (en) 2010-01-08 2011-12-01 Takeda Pharmaceutical Compounds and their use
WO2011083315A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Compounds and their use
WO2011083316A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2012037258A1 (en) * 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives

Also Published As

Publication number Publication date
IL196094A0 (en) 2009-09-01
CA2655604C (en) 2016-08-09
CR10540A (es) 2009-02-05
CN103382174A (zh) 2013-11-06
BRPI0712823A2 (pt) 2012-07-24
SG173312A1 (en) 2011-08-29
WO2007150010A2 (en) 2007-12-27
DOP2011000283A (es) 2011-10-31
AU2007260836A1 (en) 2007-12-27
ES2533009T3 (es) 2015-04-06
NZ597498A (en) 2013-06-28
CA2655604A1 (en) 2007-12-27
UY31527A1 (es) 2009-08-03
ECSP099046A (es) 2009-02-27
RU2009102048A (ru) 2010-07-27
MX2008016343A (es) 2009-01-19
AU2007260836B2 (en) 2012-11-15
KR20090024811A (ko) 2009-03-09
NZ611323A (en) 2014-10-31
TW200808773A (en) 2008-02-16
US8829041B2 (en) 2014-09-09
JP5203360B2 (ja) 2013-06-05
JP2009541350A (ja) 2009-11-26
US20080021081A1 (en) 2008-01-24
WO2007150010A3 (en) 2008-05-02
RU2449989C2 (ru) 2012-05-10
CN101472887A (zh) 2009-07-01
EP2049472B1 (en) 2015-01-21
NO20090282L (no) 2009-03-19
EP2049472A2 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
WO2006132914A3 (en) Cyclobutyl amine derivatives
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
MY150990A (en) Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
UA97036C2 (en) Cyclopropyl amine derivatives
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MXPA05011739A (es) Derivados de quinuclidina que se enlazan con los receptores muscarinicos m3.
HK1109767A1 (en) Quaternary ammonium salts as m3 antagonists
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2007007720A (es) Derivados de pirrolidinio como receptores m3 muscarinicos.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2010151815A3 (en) 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
HK1128462A1 (en) Novel method for preparation of ammonium salts of esomeprazole
UA94242C2 (ru) Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3
IN2014DN04587A (ru)
TNSN05279A1 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
MX2009005388A (es) Derivados de acetileno como inhibidores de estearoil coa desaturasa.